Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc (AGEN) is a clinical-stage biotechnology company pioneering novel immunotherapies to combat cancer and infectious diseases. This page provides centralized access to official press releases, financial updates, and scientific developments from Agenus, offering stakeholders a reliable resource for tracking the company’s progress.
Investors and researchers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships, alongside analyses of AGEN’s proprietary platforms like Retrocyte Display™ antibody technology. The curated news collection enables efficient monitoring of the company’s immuno-oncology pipeline and manufacturing advancements through its integrated cGMP facilities.
Key categories include earnings reports, therapy development updates, licensing agreements, and peer-reviewed research highlights. Bookmark this page to stay informed about AGEN’s innovations in checkpoint modulators, cell therapies, and vaccine adjuvants without navigating multiple sources.
Ligand Pharmaceuticals and Agenus have entered into a $100 million royalty financing agreement to support Agenus' key development initiatives in the BOT/BAL clinical development program. Ligand will pay $75 million initially and can invest an additional $25 million. They will receive royalties and milestone payments on six Agenus-partnered programs and future global net sales generated by BOT/BAL. Agenus can syndicate up to $125 million, with potential total capital infusion of $200 million. The partnership aims to advance transformative cancer treatments, including the BOT/BAL regimen.
Agenus Inc. has regained compliance with the minimum bid price requirement of $1.00 set by NASDAQ, ensuring continued listing on the NASDAQ Capital Market. The company focuses on immunology-based therapies for cancer, offering a robust pipeline of immunological agents. Agenus aims to enhance patient populations benefiting from cancer immunotherapy through combination approaches utilizing various antibody therapeutics, adoptive cell therapies, and adjuvants. Headquartered in Lexington, MA, Agenus is committed to advancing treatments for cancer and infectious diseases.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
